New psoriasis pill shows promise in major trial

NCT ID NCT07432854

First seen Apr 01, 2026 · Last updated May 08, 2026 · Updated 6 times

Summary

This study tests a new tablet called CMS-D001 for adults with moderate to severe plaque psoriasis. About 540 people will take either the drug or a placebo to see if it improves skin symptoms like redness and scaling. The goal is to find a safe and effective treatment option.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MODERATE TO SEVERE PLAQUE PSORIASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Affiliated Hospital of Chengde Medical College

    Chengde, Hebei, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Affiliated Hospital of Hebei University of Engineering

    Handan, Hebei, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Beijing Tongren Hospital Affiliated to Capital Medical University

    Beijing, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Hangzhou First People's Hospital

    Hangzhou, Zhejiang, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Hangzhou Third People's Hospital

    Hangzhou, Zhejiang, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Henan Provincial People's Hospital

    Zhengzhou, Henan, China

    Contact Phone: •••-•••-••••

  • Jining First People's Hospital

    Jining, Shandong, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Nanyang Central Hospital

    Nanyang, Henan, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Sanmenxia Central Hospital

    Sanmenxia, Henan, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Shandong First Medical University Affiliated Dermatology Hospital

    Jinan, Shangdong, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Shanghai Dermatology Hospital

    Shanghai, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Shijiazhuang Traditional Chinese Medicine Hospital

    Shijiazhuang, Hebei, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Southern Medical University Dermatology Hospital

    Guangzhou, Guangdong, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The First Affiliated Hospital of Bengbu Medical College

    Bengbu, Anhui, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The First Affiliated Hospital of Wannan Medical College (Yijishan)

    Wuhu, Anhui, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The First Hospital of Jilin University

    Changchun, Jilin, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The Fourth Affiliated Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The Second Affiliated Hospital of Harbin Medical University

    Harbin, Heilongjiang, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Wuxi Second People's Hospital

    Wuxi, Jiangsu, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Zhejiang Provincial People's Hospital

    Hangzhou, Zhejiang, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Zhujiang Hospital of Southern Medical University

    Guangzhou, Guangdong, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.